arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Genprex, Inc.

GNPX
$4.26 ▼ -0.21 (-4.70%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
40 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Genprex, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $29.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -21.0%
FCF / Share $-0.45
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-4.46M
↓ -12.5%
FCF / Share Free cash flow per share
$-0.45
↓ -65.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 40 quarters